RecruitingNCT06961968
Iloperidone injection to prevent schizophrenia relapse
About this title
Read the official source — NCT06961968Medication studyAges 18–65United States
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Rogers and 21 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 14, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 400
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06961968
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Rogers · Costa Mesa · Lemon Grove
19 more locations
- Oceanside
- Pico Rivera
- San Diego
- Walnut Creek
- North Miami
- Atlanta
- Peachtree Corners
- Chicago
- Flowood
- Saint Charles
- St Louis
- Las Vegas
- Marlton
- Staten Island
- Austin
- Houston
- Irving
- Richardson
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including iloperidone and placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
